Home Cart Sign in  
Chemical Structure| 175519-16-1 Chemical Structure| 175519-16-1

Structure of Voreloxin HCl
CAS No.: 175519-16-1

Chemical Structure| 175519-16-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Voreloxin HCl is a naphthyridine analogue with antineoplastic activity and an inhibitor of Topo II.

Synonyms: AG 7352 Hydrochloride; Vosaroxin Hydrochloride; Vosaroxin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Voreloxin HCl

CAS No. :175519-16-1
Formula : C18H20ClN5O4S
M.W : 437.90
SMILES Code : [H]Cl.O=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[C@H](OC)[C@@H](NC)C4)=N3)C1=O)O
Synonyms :
AG 7352 Hydrochloride; Vosaroxin Hydrochloride; Vosaroxin
MDL No. :MFCD13185156

Safety of Voreloxin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Voreloxin HCl

DNA

Isoform Comparison

Biological Activity

Target
  • Topo II

In Vitro:

Cell Line
Concentration Treated Time Description References
Human cells 100 μM 3 days Screening for human cells resistant to Voreloxin Nucleic Acids Res. 2019 Sep 5;47(15):8163-8179.
Yeast cells 100 μM 3 days Screening for yeast cells resistant to Voreloxin Nucleic Acids Res. 2019 Sep 5;47(15):8163-8179.
MOLT-4 cells 300 nM 24 hours To evaluate the anti-proliferative effects of the combination of VX-11e and voreloxin on leukemia cells, showing synergistic effects in MOLT-4 cells. Apoptosis. 2019 Dec;24(11-12):849-861.
REH cells 22 nM 24 hours To evaluate the anti-proliferative effects of the combination of VX-11e and voreloxin on leukemia cells, showing synergistic effects in REH cells. Apoptosis. 2019 Dec;24(11-12):849-861.
K562 cells 50 nM 24 hours To evaluate the anti-proliferative effects of the combination of VX-11e and voreloxin on leukemia cells, showing additive, antagonistic, and one synergistic effect in K562 cells. Apoptosis. 2019 Dec;24(11-12):849-861.
MOLM-14 cells 160 nM 24 hours To evaluate the anti-proliferative effects of the combination of VX-11e and voreloxin on leukemia cells, showing synergistic effects in MOLM-14 cells. Apoptosis. 2019 Dec;24(11-12):849-861.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01980056 Myelodysplastic Syndrome PHASE1|PHASE2 COMPLETED 2015-01-19 Weill Cornell Medical College,... More >> New York, New York, 10065, United States Less <<
NCT00246662 Leukemia, Lymphocytic, Acute|L... More >>eukemia, Nonlymphocytic, Acute|Leukemia, Myeloid, Chronic|Myelodysplastic Syndromes Less << PHASE1 COMPLETED 2025-04-09 H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States|Indiana University Cancer Center, Indianapolis, Indiana, 46202, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21231, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, 87196, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.42mL

2.28mL

1.14mL

22.84mL

4.57mL

2.28mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories